Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257511 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2259990 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2221066 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2218438 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2258838 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2254789 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2256002 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2255838 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2255273 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 | |
| SCHEMBL2255062 | 1.00 | DGKA (0.61) | DGKALMNATSHRPAMCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-RE39112-E1 | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes | EISAI CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | SANKYO COMPANY, LIMITED (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1568704-A1 | NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1221444-B1 | FUSED IMIDAZOLE COMPOUNDS AND REMEDIES FOR DIABETES MELLITUS | EISAI CO LTD (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-6841549-B1 | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus | EISAI CO., LTD. (JP) | 2005-01-11 | — | — | US | disclosed |
| US-6703388-B2 | DIBENZODIAZEPINE DERIVATIVES; ANTIHISTAMINES, LEUKOTRIENE INHIBITORS, ANTIALLERGENS, ANTIASTHMATICS; HAY FEVER, ATOPIC DERMATITIS, AND URTICARIA TREATMENT | EISAI CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-0671172-A1 | AMINO ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-09-13 | — | — | EP | disclosed |
| US-5444066-A | Thioformamide derivatives having hypotensive activity | EISAI CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| WO-1994022855-A1 | NITROGEN-CONTAINING FUSED-HETEROCYCLE COMPOUNDS | EISAI CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| EP-0609442-A1 | THIOFORMAMIDE DERIVATIVE | Eisai Co., Ltd. (JP) | 1994-08-10 | — | — | EP | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-5329010-A | Unsaturated groups with heteroarylalkyl groups and carboxy derivatives | EISAI CO., LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| EP-0503426-A1 | Quinone derivatives | Eisai Co., Ltd. (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0484966-A2 | 7-Acyl-3-(substituted carbamoyloxy) cephem compounds, use thereof and process for their preparation | Eisai Co., Ltd. (JP) | 1992-05-13 | — | — | EP | disclosed |
| US-5073551-A | Antibiotics | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-12-17 | — | — | US | disclosed |
| EP-0335390-A2 | Novel cephalosporin compounds | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | NSUN2, RNGTT, NSUN3 | DGKA 4227/4885LMNA 2237/4885TSHR 1870/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | DGKA 3822/4885LMNA 2298/4885TSHR 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.